We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Metabolomics Analysis Applied to Investigate MPS

By LabMedica International staff writers
Posted on 17 Oct 2017
Print article
Image: The Synapt G2 high definition mass spectrometer (HDMS) (Photo courtesy of Waters).
Image: The Synapt G2 high definition mass spectrometer (HDMS) (Photo courtesy of Waters).
Inborn errors of metabolism (IEM) represent a group of about 500 rare diseases with an overall estimated incidence of 1/2,500. The diversity of involved metabolisms explains the difficulties in establishing their diagnosis.

Lysosomal storage diseases (LSD) represent a group of about 50 inherited disorders due to lysosomal proteins deficiencies, which lead to a progressive accumulation of compounds within the lysosome. This metabolite storage causes various organ failures and premature death and Mucopolysaccharidoses (MPS) belong to the LSD group.

Clinical biochemists and their colleagues working with those at Rouen University Hospital (Rouen, France) applied targeted and untargeted metabolic profiling in urine samples obtained from a French cohort comprising 19 Mucopolysaccharidosis (MPS) I and 15 MPS I treated patients along with 66 controls. Random urine samples were collected from MPS patients in whom the diagnosis had been confirmed by demonstrating marked enzyme deficiency in leucocytes and/or by molecular analysis.

Ultra-high-performance liquid chromatography-ion mobility mass spectrometry and data-independent MS acquisitions with simultaneous analysis of molecular fragmentation (MSE) were performed on Synapt G2 HDMS mass spectrometer. All LC-IM/MS raw data files, data processing, peak detection and peak matching across samples using retention time correction and chromatographic alignment along with drift time and cross collision section (CCS) calculation were performed using Progenesis QI (Waters MS Technologies, Manchester, UK). The analysis of free amino acid profiles in urine was based on a liquid chromatography coupled to tandem mass spectrometry method and the aTRAQ reagent.

The scientists reported that the studied groups yielded distinct biochemical phenotypes using multivariate data analysis. Univariate statistics also revealed metabolites that differentiated the groups. Specifically, metabolites related to the amino acid metabolism. Pathway analysis revealed that several major amino acid pathways were dysregulated in MPS. Comparison of targeted and untargeted metabolomics data with in silico results yielded arginine, proline and glutathione metabolisms being the most affected.

The authors concluded that metabolic phenotyping enabled them to unveil profound metabolic impairments beyond the primary deficiency in MPS I. The understanding of disease pathophysiological bases may open new therapeutic strategies such as antioxidants adjuvants and diet intervention as complementary treatments for MPS and possibly for other LSDs. The study was published on October 2, 2017, in the journal Clinica Chemica Acta.

Related Links:
Rouen University Hospital

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.